Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
